Piper Sandler: 'We Are Naming Capricor Therapeutics (CAPR) As a 2026 Top Pick'
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $45.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
